Savara Stock (NASDAQ:SVRA)
Previous Close
$4.60
52W Range
$1.89 - $4.91
50D Avg
$3.86
200D Avg
$3.02
Market Cap
$950.19M
Avg Vol (3M)
$1.60M
Beta
0.27
Div Yield
-
SVRA Company Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.